An observational study in OPA1 Gene Mutation and Optic Atrophy, Autosomal Dominant, sponsored by Ludwig-Maximilians - University of Munich. Recruiting at 1 site in Germany. Per ClinicalTrials.gov, last updated 2026-07-28.
Sponsored by Ludwig-Maximilians - University of Munich · Observational
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
This prospective, monocenter, non-interventional observational study investigates the natural history as well as the clinical and genetic spectrum of OPA1-associated autosomal dominant optic atrophy. Participants will undergo standardized ophthalmic and functional assessments, including visual acuity testing, visual field testing, color vision and contrast sensitivity testing, optical coherence tomography, retinal flavoprotein fluorescence imaging, and video-oculography-based ocular motor and pupillary measurements. The study aims to characterize disease severity and progression over time and to identify structural, metabolic, and functional biomarkers that may serve as clinical endpoints for future therapeutic studies.
Ludwig-Maximilians - University of Munich is the lead sponsor of 223 studies on the registry; 29 are open to participants now.
Counted across the registry records on this site, refreshed daily.
Participants will be recruited from the inherited retinal disease and ophthalmogenetics clinic of the Department of Ophthalmology, University Hospital, Ludwig-Maximilians-Universität München, Germany. The study population consists of patients followed at this tertiary referral center. Additional participants may be referred by genetic diagnostic centers or other physicians in Germany or abroad after molecular genetic testing and clinical suspicion of OPA1-related disease. Self-referral by patients with a previous diagnosis of OPA1-associated autosomal dominant optic atrophy is also accepted.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
(Participants are eligible for inclusion if all of the criteria mentioned above are met)
Exclusion Criteria:
- Severe systemic disease or medical condition that, in the opinion of the investigator, would preclude participation in the study-related examinations
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Informed consent
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Change in 2.5% low-contrast visual acuity measured with Sloan letter charts
Change from baseline in low-contrast visual acuity measured using 2.5% low-contrast Sloan letter charts. Low-contrast visual acuity will be recorded as the number of Sloan letters correctly read and may be converted to logMAR for analysis. The unit of measure is number of Sloan letters correctly read.
Time frame: Baseline and follow-up visits up to 3 years
Change in contrast sensitivity
Change from baseline in contrast sensitivity measured using the Manifold® Platform from Adaptive Sensory Technology. The unit of measure is log contrast sensitivity.
Time frame: Baseline and follow-up visits up to 3 years
Change in macular ganglion cell layer thickness measured by optical coherence tomography
Change from baseline in macular ganglion cell layer thickness, or ganglion cell-inner plexiform layer thickness where applicable, measured by optical coherence tomography. The unit of measure is micrometers.
Time frame: Baseline and follow-up visits up to 3 years
Change in peripapillary retinal nerve fiber layer thickness measured by optical coherence tomography
Change from baseline in peripapillary retinal nerve fiber layer thickness measured by optical coherence tomography. The unit of measure is micrometers.
Time frame: Baseline and follow-up visits up to 3 years
Change in retinal flavoprotein fluorescence intensity measured by flavoprotein fluorescence imaging
Change from baseline in retinal autofluorescence intensity measured using the OcuMet Beacon confocal scanning ophthalmoscope. The unit of measure is a device-specific autofluorescence intensity score.
Time frame: Baseline and follow-up visits up to 3 years
Change in central visual field sensitivity measured by Humphrey 10-2 automated perimetry
Change from baseline in central visual field sensitivity measured using Humphrey 10-2 automated perimetry. The unit of measure is decibels.
Time frame: Baseline and follow-up visits up to 3 years
Change in protan and tritan colour contrast thresholds measured by the Arden Colour Contrast Test
Change from baseline in protan and tritan colour contrast thresholds measured using the Arden Colour Contrast Test. Protan and tritan thresholds will be reported separately. The unit of measure is percent contrast.
Time frame: Baseline and follow-up visits up to 3 years
Change in best-corrected visual acuity (BCVA) measured with high-contrast visual acuity testing
Change from baseline in best-corrected visual acuity (BCVA) measured using standardized high-contrast visual acuity testing. BCVA will be recorded as the number of letters correctly read or converted to logMAR for analysis. The unit of measure is logMAR or number of letters correctly read.
Time frame: Baseline and follow-up visits up to 3 years
Change in pupil diameter measured by video-oculography using BulbiCAM
Change from baseline in pupil diameter measured by video-oculography using the BulbiCAM Pupil Dynamics test. The unit of measure is millimeters.
Time frame: Baseline and follow-up visits up to 3 years
Change in pupillary peak velocity measured by video-oculography using BulbiCAM
Change from baseline in pupillary peak constriction and dilation velocity measured by video-oculography using the BulbiCAM Pupil Dynamics test. Constriction and dilation velocity will be reported separately. The unit of measure is millimeters per second.
Time frame: Baseline and follow-up visits up to 3 years
Change in cumulative fixation time measured by BulbiCAM Fixation test
Change from baseline in the cumulative fixation time measured using the BulbiCAM. The unit of measure is seconds.
Time frame: Baseline and follow-up visits up to 3 years
Change in smooth pursuit gain measured by video-oculography using BulbiCAM
Change from baseline in device-derived smooth pursuit gain measured during the BulbiCAM Smooth Pursuit test. The unit of measure is percent.
Time frame: Baseline and follow-up visits up to 3 years
Change in objective central visual field sensitivity measured by KONAN ObjectiveFIELD Analyzer
Change from baseline in objective central visual field sensitivity measured using the KONAN ObjectiveFIELD Analyzer with multifocal pupillographic objective perimetry. The unit of measure is decibels.
Time frame: Baseline and follow-up visits up to 3 years
Plan to share: No
No publications or documents are linked to this record.
Started Jul 2026 (actual). Primary completion is estimated for Oct 2030, 51 months after the start.
How these figures are worked out, and which studies are left out of them.
Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.
Contact study teamGet an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Optic Atrophy, Autosomal Dominant
Ludwig-Maximilians - University of Munich →